{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-072646","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.469180+00:00","generated_at":"2026-06-18T00:45:36.388651+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eliem Therapeutics Announces CFO Resignation and Appoints New Principal Financial and Accounting Officers","bullets":["Erin Lavelle resigned as EVP, COO, and CFO effective March 10, 2023.","Andrew Levin, Executive Chairman, appointed as principal financial officer (in addition to principal executive officer).","Emily Pimblett, Chief Accounting Officer, appointed as principal accounting officer.","Levin is a co-founder and managing director at RA Capital Management; Pimblett previously held roles at DomainTools and Avvo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-072646","json":"https://secwatch.observer/filing/0001193125-23-072646.json","markdown":"https://secwatch.observer/filing/0001193125-23-072646.md","text":"https://secwatch.observer/filing/0001193125-23-072646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/d461584d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:45:36.388651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"265db50566","claim":"Andrew Levin was appointed as principal financial officer at Climb Bio, Inc..","evidence_excerpt":"Effective as of March 10, 2023 (the “Transition Date”), the Board appointed (i) Andrew Levin, Executive Chairman, as the Company’s new principal financial officer (in addition to principal executive officer)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"460672c7bc","claim":"Emily Pimblett was appointed as principal accounting officer at Climb Bio, Inc..","evidence_excerpt":"and (ii) Emily Pimblett, Chief Accounting Officer, as the Company’s principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"88f5637394","claim":"Erin Lavelle resigned as Executive Vice President, Chief Operating Officer and Chief Financial Officer at Climb Bio, Inc..","evidence_excerpt":"the Company and Erin Lavelle mutually agreed that Ms. Lavelle would resign as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523072646/0001193125-23-072646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief Operating Officer and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}